Inventor · disambiguated record
Melissa Fleury
Also filed as: FLEURY MELISSA
98 granted patents·11 pending applications·916 citations·filing 2005–2024
99Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC56FLEURY MELISSA11IDEAYA BIOSCIENCES INC11THERAVANCE RESPIRATORY CO LLC9HUGHES ADAM D6
Top patents by PatentIndex Score
109 records- 0198US10526330B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 7, 2020·15 cites·13 claims
- 0298US10100049B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Oct 16, 2018·28 cites·17 claims
- 0398US9126956B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2013·Granted Sep 8, 2015·51 cites·43 claims
- 0498US9108934B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2013·Granted Aug 18, 2015·51 cites·28 claims
- 0598US8871792B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2013·Granted Oct 28, 2014·53 cites·24 claims
- 0698US8691868B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2012·Granted Apr 8, 2014·57 cites·31 claims
- 0798US8586536B2Neprilysin inhibitorsGENDRON ROLAND·Filed 2011·Granted Nov 19, 2013·72 cites·26 claims
- 0898US8481044B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2012·Granted Jul 9, 2013·67 cites·29 claims
- 0997US9725470B2Substituted naphthyridines as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Aug 8, 2017·27 cites·19 claims
- 1097US8449890B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2012·Granted May 28, 2013·68 cites·26 claims
- 1196US8686184B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2012·Granted Apr 1, 2014·61 cites·25 claims
- 1296US8563512B2Neprilysin inhibitorsSMITH CAMERON·Filed 2011·Granted Oct 22, 2013·62 cites·22 claims
- 1395US10028960B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jul 24, 2018·18 cites·13 claims
- 1495US9873685B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 23, 2018·10 cites·7 claims
- 1595US9670186B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2015·Granted Jun 6, 2017·12 cites·7 claims
- 1694US10189823B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 29, 2019·9 cites·3 claims
- 1794US9845332B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Dec 19, 2017·7 cites·1 claims
- 1894US9120747B2Neprilysin inhibitorsGENDRON ROLAND·Filed 2013·Granted Sep 1, 2015·16 cites·16 claims
- 1994US8846913B2Neprilysin inhibitorsTHERAVANCE INC·Filed 2013·Granted Sep 30, 2014·18 cites·10 claims
- 2094US7956054B2Dual-acting pyrazole antihypertensive agentsTHERAVANCE INC·Filed 2010·Granted Jun 7, 2011·21 cites·16 claims
- 2193US11299492B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 12, 2022·2 cites·13 claims
- 2293US11230536B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 25, 2022·2 cites·20 claims
- 2393US11084798B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Aug 10, 2021·3 cites·26 claims
- 2492US11124502B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Sep 21, 2021·2 cites·20 claims
- 2592US10570120B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 25, 2020·6 cites·20 claims
- 2692US9688692B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jun 27, 2017·7 cites·11 claims
- 2792US9388145B2Neprilysin inhibitorsGENDRON ROLAND·Filed 2015·Granted Jul 12, 2016·8 cites·9 claims
- 2892US8901169B2Neprilysin inhibitorsFENSTER ERIK·Filed 2014·Granted Dec 2, 2014·14 cites·31 claims
- 2991US9682957B2Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activityTHERAVANCE RESPIRATORY CO LLC·Filed 2016·Granted Jun 20, 2017·5 cites·2 claims
- 3091US9572802B2Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activityTHERAVANCE RESPIRATORY CO LLC·Filed 2016·Granted Feb 21, 2017·5 cites·30 claims
- 3191US9533962B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 3, 2017·6 cites·28 claims
- 3291US8138345B2Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activityHUGHES ADAM·Filed 2010·Granted Mar 20, 2012·13 cites·3 claims
- 3390US11130759B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Sep 28, 2021·2 cites·26 claims
- 3490US11046691B12-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitorsIDEAYA BIOSCIENCES INC·Filed 2021·Granted Jun 29, 2021·2 cites·28 claims
- 3590US10744104B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 18, 2020·2 cites·20 claims
- 3690US9975875B2Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activityTHERAVANCE RESPIRATORY CO LLC·Filed 2017·Granted May 22, 2018·4 cites·3 claims
- 3790US9499487B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2012·Granted Nov 22, 2016·12 cites·10 claims
- 3889US12358931B23-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitorTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Jul 15, 2025·0 cites·5 claims
- 3989US11718591B2Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Aug 8, 2023·1 cites·20 claims
- 4089US11110095B2Pyrimidine compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Sep 7, 2021·3 cites·22 claims
- 4189US9872855B2(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·5 cites·9 claims
- 4289US9771350B2Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activityTHERAVANCE RESPIRATORY CO LLC·Filed 2017·Granted Sep 26, 2017·4 cites·2 claims
- 4389US7642339B2Antiviral compoundsGILEAD SCIENCES INC·Filed 2005·Granted Jan 5, 2010·15 cites·9 claims
- 4488US12016835B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jun 25, 2024·0 cites·16 claims
- 4588US11033533B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 4688US9682052B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2015·Granted Jun 20, 2017·4 cites·37 claims
- 4787US11919888B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Mar 5, 2024·0 cites·6 claims
- 4887US11261197B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Mar 1, 2022·1 cites·20 claims
- 4987US10829438B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 10, 2020·1 cites·20 claims
- 5087US10472335B2Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereofTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Nov 12, 2019·4 cites·15 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Melissa Fleury files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →